Q2 2025 Absci Corp Earnings Call Transcript
Key Points
- Absci Corp (ABSI) initiated Phase 1 clinical trials for ABS-101, a potential best-in-class anti-TL1A antibody, with interim results expected later this year.
- The company is advancing ABS-201, an innovative anti-prolactin receptor antibody for androgenetic alopecia, with plans to initiate a Phase 1 trial in early 2026.
- Absci Corp (ABSI) has a strong interest from potential partners for its TL1A antibody and bispecific programs, indicating robust external validation.
- The company raised approximately $64 million in gross proceeds, strengthening its balance sheet and extending its cash runway into the first half of 2028.
- Absci Corp (ABSI) continues to advance its AI-integrated drug creation platform, with a strategic investment from AMD, enhancing its capabilities in drug discovery.
- Revenue for the second quarter was only $600,000, indicating limited income from current operations.
- Research and development expenses increased to $20.5 million, reflecting higher costs associated with advancing internal programs.
- The company experienced a decrease in cash, cash equivalents, and short-term investments from $134 million to $117.5 million as of June 30, 2025.
- Absci Corp (ABSI) faces competition from big pharma companies with advanced AI-based drug discovery systems, posing a challenge to its competitive edge.
- The development timeline for ABS-201 suggests potential commercialization only by 2030-2031, indicating a long path to market entry.
Ladies and gentlemen, thank you for standing by. Welcome to Absci second-quarter 2025 business update call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to turn the conference over to Alex Khan, Vice President of Finance and Investment Relations. Please go ahead.
Thank you. Earlier today, Absci released financial and operating results for the quarter ended June 30, 2025. If you haven't received this news release, or if you would like to be added to the company's distribution list, please send an email to [email protected]. An archived webcast of this call will be available for replay on Absci Investor Relations website at investors.absci.com for at least 90 days after this call.
Joining me today are Sean McClain, Absci's Founder and CEO; and Zach Jonasson, Chief Finance and Chief Business Officer. Christian Stegmann, Absci's SVP of Drug Creation, will also join for Q&A following prepared remarks.
Before
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
